Neuren Pharmaceuticals Limited (ASX:NEU)
18.58
+0.46 (2.54%)
Nov 7, 2025, 4:10 PM AEST
Neuren Pharmaceuticals Balance Sheet
Financials in millions AUD. Fiscal year is January - December.
Millions AUD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 5.91 | 3.15 | 17.09 | 40.18 | 36.78 | 24.19 | Upgrade |
Short-Term Investments | 293.63 | 219.09 | 211.45 | - | - | - | Upgrade |
Cash & Short-Term Investments | 299.54 | 222.24 | 228.54 | 40.18 | 36.78 | 24.19 | Upgrade |
Cash Growth | 40.51% | -2.76% | 468.79% | 9.23% | 52.07% | 74.72% | Upgrade |
Accounts Receivable | 20.52 | 172.91 | 12.8 | - | 0.01 | - | Upgrade |
Other Receivables | 0.19 | 2.42 | 1.61 | 1.09 | 1.42 | 0.76 | Upgrade |
Receivables | 20.71 | 175.33 | 14.41 | 1.09 | 1.42 | 0.76 | Upgrade |
Prepaid Expenses | - | 0.4 | 4.21 | 1.98 | 1.84 | - | Upgrade |
Other Current Assets | - | 1.36 | - | - | - | - | Upgrade |
Total Current Assets | 320.25 | 399.33 | 247.16 | 43.25 | 40.04 | 24.94 | Upgrade |
Property, Plant & Equipment | 0.03 | 0.03 | 0.04 | 0.02 | 0.01 | 0.01 | Upgrade |
Long-Term Deferred Tax Assets | 10.98 | 10.35 | 0.77 | - | - | - | Upgrade |
Total Assets | 331.25 | 409.71 | 247.97 | 43.27 | 40.06 | 24.95 | Upgrade |
Accounts Payable | 6.66 | 1.45 | 0.68 | 0.26 | 0.25 | 0.17 | Upgrade |
Accrued Expenses | - | 1.45 | 2.74 | 0.72 | 0.56 | 0.59 | Upgrade |
Current Income Taxes Payable | - | 42.87 | 37.12 | - | - | - | Upgrade |
Other Current Liabilities | 1.26 | - | 2.23 | 0.7 | - | - | Upgrade |
Total Current Liabilities | 7.92 | 45.76 | 42.76 | 1.68 | 0.8 | 0.75 | Upgrade |
Pension & Post-Retirement Benefits | 0.06 | 0.04 | - | - | - | - | Upgrade |
Total Liabilities | 7.98 | 45.8 | 42.76 | 1.68 | 0.8 | 0.75 | Upgrade |
Common Stock | 127.59 | 165.27 | 173.13 | 167.74 | 167.58 | 145.57 | Upgrade |
Retained Earnings | 195.46 | 180.43 | 38.39 | -118.69 | -118.88 | -111.08 | Upgrade |
Comprehensive Income & Other | 0.22 | 18.2 | -6.31 | -7.46 | -9.45 | -10.28 | Upgrade |
Total Common Equity | 323.27 | 363.9 | 205.21 | 41.59 | 39.25 | 24.2 | Upgrade |
Shareholders' Equity | 323.27 | 363.9 | 205.21 | 41.59 | 39.25 | 24.2 | Upgrade |
Total Liabilities & Equity | 331.25 | 409.71 | 247.97 | 43.27 | 40.06 | 24.95 | Upgrade |
Net Cash (Debt) | 299.54 | 222.24 | 228.54 | 40.18 | 36.78 | 24.19 | Upgrade |
Net Cash Growth | 40.51% | -2.76% | 468.79% | 9.23% | 52.07% | 74.72% | Upgrade |
Net Cash Per Share | 2.31 | 1.70 | 1.75 | 0.31 | 0.31 | 0.23 | Upgrade |
Filing Date Shares Outstanding | 124.49 | 127.01 | 127.27 | 125.97 | 125.97 | 114.61 | Upgrade |
Total Common Shares Outstanding | 124.49 | 127.01 | 127.27 | 125.97 | 125.97 | 114.61 | Upgrade |
Working Capital | 312.32 | 353.57 | 204.39 | 41.57 | 39.24 | 24.19 | Upgrade |
Book Value Per Share | 2.60 | 2.87 | 1.61 | 0.33 | 0.31 | 0.21 | Upgrade |
Tangible Book Value | 323.27 | 363.9 | 205.21 | 41.59 | 39.25 | 24.2 | Upgrade |
Tangible Book Value Per Share | 2.60 | 2.87 | 1.61 | 0.33 | 0.31 | 0.21 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.